<DOC>
	<DOCNO>NCT00292877</DOCNO>
	<brief_summary>The purpose study determine treatment anti-IL-5 antibody prednisone-sparing effect patient symptomatic eosinophilic bronchitis ( without asthma ) .</brief_summary>
	<brief_title>The Prednisone-sparing Effect Anti-IL-5 Antibody ( SB-240563 )</brief_title>
	<detailed_description>Eosinophilic bronchitis , identify quantitative sputum cell count ( eosinophil great 2 % ) responsive corticosteroid treatment . It occur alone association asthma patient chronic obstructive pulmonary disease ( COPD ) . In patient eosinophilic bronchitis responds treatment inhale steroid require minimum dose prednisone keep control . At present , outstanding drug prednisone-sparing effect . Interleukin ( IL ) -5 cytokine specifically focus development , differentiation , recruitment , activation survival eosinophil . The specificity IL-5 raise possibility block 's activity , use humanize monoclonal antibody , may useful therapy eosinophilic bronchitis . Such antibody ( SB-240563 ) introduce clinical trial . The investigator compare effect versus placebo patient prednisone-dependant symptomatic eosinophilic bronchitis ( without asthma ) reduction prednisone dose identify prednisone-sparing effect . The study divide 3 sequential study period . Period 1 : symptomatic eosinophilic bronchitis ( without asthma ) dose prednisone 6-weeks . Period 2 : standardize prednisone reduction ( inhaled steroid prednisone discontinue study treatment ) intervals 4-weeks clinical eosinophilic exacerbation bothersome steroid withdrawl effect . Period 3 : washout . The patient see every 2 week . Intravenous injection SB-240563 750mg placebo give week 2,6,10,14 18 . Doses prednisone reduce standard way .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Adult patient , age 1870 year , follow outpatient found require minimum dose prednisone treatment ( addition highdose inhaled steroid treatment ) prevent frequent exacerbation associate induced sputum eosinophilia . 2 . Patients enrol , screen baseline visit , demonstrate sputum eosinophilia symptom . The symptom may effect activity sleep , opinion treat physician , severe enough concern . 3 . While FEV1 withhold bronchodilator appropriately , inhale salbutamol ( 200 mg ) , methacholine PC20 measure , need abnormal since prednisone require control eosinophilic bronchitis clinical consequence , bronchitis occur without feature asthma . 4 . On dos corticosteroid least onemonth . 1 . Pregnancy , breastfeed lack effective contraception female childbearing potential female postmenopausal &lt; 1 year . 2 . Baseline FEV1 bronchodilator 40 % less predict . This low FEV1 acceptable since chronic airflow limitation secondary eosinophilic bronchitis asthma exclusion criterion . Neither current excigarette smoking provide best FEV1 patient &gt; 60 % predict normal best FEV1/VC ratio &gt; 60 % past two year . 3 . Exposure relevant seasonal environmental allergen , know worsen asthma control , study period . 4 . Respiratory tract infection 4weeks baseline visit . 5 . Clinical exacerbation require extra prednisone treatment 4weeks V1 . 6 . Other cardiac , pulmonary , renal systemic disease investigator 's opinion may interfere study result compromise subject 's safety . 7 . Previous participation study use antimonoclonal drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>1 . Eosinophilic bronchitis , 2 . Asthma , 3 . Steroid dependent asthma , 4 . Sputum eosinophils , 5 . SB-240563 ( Mepolizumab )</keyword>
</DOC>